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Abstract
Background: The mode of medical cannabis delivery—whether cannabis is smoked, vapourized, or consumed
orally—may have important implications for its therapeutic efficacy and health risks. However, there is very little
evidence on current patterns of use among Canadian medical cannabis users, particularly with respect to modes
of delivery. The current study examined modes of medical cannabis delivery following regulatory changes in
2014 governing how Canadians access medical cannabis.
Methods: A total of 364 approved adult Canadian medical cannabis users completed an online cross-sectional
survey between April and June 2015. The survey examined patterns of medical cannabis use, modes of delivery
used, and reasons for use. Participants were recruited through a convenience sample from nine Health Canada
licensed producers.
Results: Using a vapourizer was the most popular mode of delivery for medical cannabis (53 %), followed by smoking
a joint (47 %). The main reason for using a vapourizer was to reduce negative health consequences associated with
smoking. A majority of current vapourizer users reported using a portable vapourizer (67.2 %), followed by a stationary
vapourizer (41.7 %), and an e-cigarette or vape pen (19.3 %). Current use of a vapourizer was associated with fewer
respiratory symptoms (AOR = 1.28, 95 % CI 1.05–1.56, p = 0.01).
Conclusions: The findings suggest an increase in the popularity of vapourizers as the primary mode of delivery among
approved medical users. Using vapourizers has the potential to prevent some of the adverse respiratory health
consequences associated with smoking and may serve as an effective harm reduction method. Monitoring implications
of such current and future changes to medical cannabis regulations may be beneficial to policymakers.
Keywords: Medical cannabis, Policy, Population health
Background
Cannabis has a range of therapeutic benefits including as
an analgesic for pain, antispasm for multiple sclerosis,
anticonvulsive for epilepsy, nausea suppressant for chemo-
therapy, and appetite stimulant for wasting in HIV/AIDS
patients [1, 2]. Canadians were granted the legal right to
access medical cannabis in 2001 following a ruling of the
Supreme Court of Canada. In 2011, approximately 400,000
Canadians reported using cannabis for medical purposes
[3]; however, only 40,000 Canadians had received approval
to do so under Health Canada regulations as of 2013 [4, 5].
Medical cannabis can be delivered through various
modes, including smoking, eaten in foods, vapourized,
and in a spray. Although most medical cannabis users in
Canada report trying multiple modes, smoking has been
the dominant mode of delivery [6–9]. Canadian users
report several advantages for smoked modes of delivery,
including greater enjoyment, convenience and ease of
use, more immediate and effective relief of symptoms,
greater control over dosage, lower dose for desired
effect, and whole-body euphoria [10, 11]. Data from
other countries is consistent with Canadian studies, indi-
cating greater use, preference, and cost-effectiveness of
smoked delivery modes [6, 7].
Despite the appeal among users, smoked modes of de-
livery have several disadvantages. These include social dis-
approval for smoking and smell, as well as concerns about
increased health risks from smoke inhalation [11, 12].
Studies have consistently shown that cannabis smokers
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report a higher frequency of cough and sputum production,
wheezing, and bronchitis compared with non-smokers, as a
result of airway inflammation and infection [13]. In
addition, some literature reports the presence of lung
cancer among heavy cannabis smokers, as well as bullous
lung disease and emphysema [14]. Evidence on the long-
term respiratory effects of cannabis smoking is complicated
by the co-morbidity of cannabis and cigarette smoking (in-
cluding mixing tobacco and cannabis), as well as time lag
in the onset of chronic respiratory diseases [15, 16]. Never-
theless, chronic smoke inhalation from cannabis smoke is
likely to reduce respiratory health.
Alternative modes of delivery have the potential to re-
duce the negative respiratory health risks associated with
smoking cannabis. Cannabis can be consumed orally in
edibles and oro-mucosally in sprays or tinctures [2]. Oral
modes of delivery are perceived by users as healthier than
smoking, less obvious than smoking since there is no
smell, more convenient, and to have longer lasting effects
[6, 7, 11]. On the other hand, medical cannabis users have
reported that edibles do not provide the same euphoria,
are more expensive, difficult to titrate dose and prepare,
and have a slow onset of effect [6, 7, 11, 17].
Vapourization provides delivery characteristics that are
similar to smoking, with respect to the time to onset
and some sensory effects [6, 18]. However, vapourizers
do not heat marijuana to the point of combustion and,
therefore, expose users to significantly lower levels of
toxicants that are only present in smoke [13]. Chemical
analysis, self-reported data, and spirometry testing
demonstrate that vapourization of cannabis is less harm-
ful and reduces respiratory effects compared to smoking
[13, 18–21]. Users perceive vapourization similar to
smoking in terms of ease of dose titration and fast onset
of action, but with fewer side effects [6, 22]. Vapourizing
has also been reported to taste better, has no smoke
smell, and is more discreet [6, 22]. For example, a recent
international study among both medical and recreational
users found that respondents reported their vapourizer
experiences as satisfying or very satisfying and that 98 %
of those respondents indicated that they intended to
continue using a vapourizer [22]. Common disadvan-
tages associated with vapourizers include greater incon-
venience, the difficulty of using vapourizers, and the
higher cost [22].
To date, there is little evidence in Canada on the
prevalence of different modes of delivery. Although
vapourizers have been on the market for some time,
the rapid increase in the use of vapourizers to deliver
nicotine (often referred to as “e-cigarettes”) has
increased the availability of these products, while
reducing their cost [23]. The extent to which these
changes may have altered modes of delivery among med-
ical cannabis users is unclear. In addition, regulatory
changes in the way that approved users access medical
cannabis in Canada may also have implications for
common modes of delivery. Prior to April 2014, there
were limited restrictions regarding which forms of medical
cannabis were accessible to approved medical cannabis
users. However, after the Marihuana for Medical Purposes
Regulation (MMPR) was implemented in April 2014 by
Health Canada, approved users could only legally access
cannabis in dried herb form. Currently, there is no
evidence regarding the extent to which alternative modes
of delivery are being used by medical users or whether
their perceptions regarding modes of delivery have
changed.
The current study sought to examine medical cannabis
use among a sample of approved adult medical users in
Canada. In particular, the study assesses (1) the preva-
lence of different modes of delivery; (2) patterns of
vapourizer use, including frequency, form of cannabis,
and type; (3) perceptions of differing modes of delivery;
and (4) the importance placed on various dimensions
(e.g. time to onset of effect, symptom relief, cost, accessi-
bility, duration of effect, level of harm) when selecting a
mode of delivery.
Methods
Study design and protocol
An online cross-sectional survey was conducted from
April 29 until June 8, 2015. No public sampling frame
was available from which to sample approved medical
cannabis users nor was there any reliable way of
verifying approved status without disclosure of sensi-
tive health care records. Therefore, the current study
recruited approved users through licensed produ-
cers—the only legal source of medical cannabis in
Canada. At the time of the survey, a total of 16
licensed producers who were registering clients in
Canada were identified and approached to assist with
study recruitment. Nine licensed producers agreed
and sent their registered customers an email invitation
with information about how to contact the study
investigators. Eligible respondents were approved medical
cannabis users, 18 years of age or older, and reported
cannabis use in the past 30 days for health reasons.
Eligible respondents were provided with a unique pass-
word via email to access the survey. Respondents who
completed the survey received $10 as a thank you for
completing the survey, provided via an electronic gift card
or interact email payment. In order to protect confidenti-
ality and to minimize social desirability bias, email
addresses were the only personally identifying information
collected from respondents. The study received approval
from the Office of Research Ethics at the University of
Waterloo.
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Survey measures
Survey measures were drawn from previous sources and
adapted for the current study [4, 6, 7, 13, 24]. New and
adapted measures underwent cognitive interviewing with
approved medical cannabis users [25].
Sociodemographics
Ethnicity was classified as White or Non-white (including
South Asian, Chinese, Black, Filipino, Latin American,
Arab, Southeast Asian, West Asian, Korean, Japanese,
Aboriginal, or multi-racial). Education levels included Low
(completion of high school or less), Moderate (technical/
trade school, community college, or some university, but
no degree), and High (university degree or more). Respon-
dents were classified into five regions of Canada: Atlantic
(New Brunswick, Newfoundland and Labrador, Nova
Scotia, and Prince Edward Island), Prairies (Alberta,
Manitoba, and Saskatchewan), Ontario and Northern
(Ontario, Northwest Territories, and Nunavut) Quebec,
and British Columbia. Personal income levels included
Low ($0 to $40,000), Middle ($40,001 to $80,000), and
High (more than $80,001). Cigarette smoking status was
classified as not at all, occasionally, or daily.
Medical cannabis use
The amount of cannabis used was examined by asking
respondents to report on average how many grams of
marijuana they use per day, per week, or per month.
Respondents reported their frequency of cannabis use in
the past 3 months as every day, almost every day, or less
than almost every day, as well as number of uses per day.
The main medical reason for cannabis use included five
categories: Pain relief (chronic pain and fibromyalgia),
Mental health (anxiety or nerves, depression, ADHD,
bipolar, PTSD), Central nervous system (multiple sclerosis,
spinal cord injury, and epilepsy), Side effects (nausea or
vomiting and lack of appetite or weight loss), and Other in
which a text box was provided for further explanations
(other, glaucoma, cancer, insomnia).
Self-reported respiratory symptoms were examined
using six previously adapted questions [13]. An index
was used to represent the number of respiratory symp-
toms reported (0–6). Perceived harm from smoking
cannabis was assessed as Low (not at all harmful to my
health), Moderate (a little or somewhat harmful), and
High (very or extremely harmful).
Prevalence of modes of delivery
Respondents were asked to report Ever, Current (i.e. past
30 day use), and Preferred modes of delivery by selecting
from a list, as follows: smoking a joint, smoking a blunt,
smoking a pipe, smoking a bong or waterpipe, using a
vapourizer, eating in foods or baked goods (e.g. cookies,
candy), drinking (e.g. tea), taking a pill (e.g. Marinol®/
dronabinol or Cesamet®/nabilone), using a spray (e.g.
Sativex/nabiximols), and other. Respondents who cur-
rently used multiple modes of delivery were also asked
to report the percentage of use for each mode of delivery
they currently used. The use of alternative modes of
delivery refers to all non-smoking modes of delivery (i.e.
using a vapourizer, eating, drinking, taking a pill, using a
spray, or other).
Vapourizer use
Vapourizer awareness was ascertained by asking respon-
dents whether they had ever heard of “vapourizing or
vaping marijuana” before the study. Acceptability, harm
of vapourizers, and patterns of use (i.e. form, frequency,
and type), as well as reasons and barriers for using a
vapourizer, were assessed.
Perceptions and personal importance of dimensions by
mode of delivery
Perceptions of modes of delivery were examined by
asking respondents to rate 12 dimensions on a scale
from 1 to 5 for the modes of delivery “smoking”, “using
a vapourizer”, and “eating in foods”, separately (see
Table 3 for the list of dimensions). Respondents were
asked to rate the importance of reasons for selecting
modes of delivery on a scale from 1 to 5 by answering,
“How important are each of the factors to you in your
choice of how to use marijuana”.
Analysis
All analyses were conducted using SPSS, Version 22
(IBM, Illinois). Descriptive statistics (means, standard
deviation, and proportions) are reported for all pri-
mary outcomes and covariates. Two logistic regression
models examined correlates for the outcomes Current
modes of delivery (0 = smoked only, 1 = alternative)
and Current use of vapourizers (0 = non-current use
of a vapourizer, 1 = current use of a vapourizer). A
linear regression model also examined correlates for
the outcome respiratory symptoms (ranged from 0 =
no respiratory symptoms to 6 = severe respiratory
symptoms). The following set of covariates were en-
tered into all models: age, gender, ethnicity, educa-
tion, income, main medical reason, and perception of
harm of smoking, with the addition of respiratory
symptoms and cigarette smoking status included as
covariates in the Current modes of delivery model
and respiratory symptoms in the Current use of
vapourizer model. Adjusted odds ratios (AOR) and 95
% confidence intervals (95 % CI) are reported. In
addition, an ANOVA was used to examine differences
in perceptions of three modes of delivery.
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Results
Sample characteristics
A total of 364 respondents completed the survey after
deleting cases with missing information for age (n = 1),
gender (n = 8), and incorrect responses to a data integ-
rity question (n = 27). The survey’s completion rate
(COMR) was 79.4 % using The American Association
for Public Opinion Research standards [26].
Table 1 shows sample characteristics. As Table 1 indi-
cates, more than half of the sample was male, approxi-
mately 75 % were “White”, and approximately half lived
in Ontario. The most common medical reason was pain
relief, and a majority of respondents use cannabis more
than once a day.
Prevalence of modes of delivery
Table 2 shows the prevalence of Ever, Current, and Pre-
ferred modes of delivery. The most common Ever mode
of delivery tried was smoking a joint, whereas using a
spray was the least common. Respondents reported Ever
use of a mean of 5.4 (SD = 2.2) modes of delivery.
The most common Current and Preferred mode of
delivery was a vapourizer (see Table 2). Respondents
reported Current use of a mean of 2.4 (SD = 1.3) modes
of delivery. Among those who reported multiple modes,
smoking a joint was reported 53.1 % (SD = 36.8) of the
time, followed by 52.4 % (SD = 36.4) using a vapourizer,
43.5 % (SD = 39.6) other, 36.1 % (SD = 31.4) smoking a
bong or waterpipe, 31.6 % (SD = 31.8) smoking a pipe,
26.4 % (SD = 25.8) taking a pill, 25.0 % (SD = 29.3) eating
in foods or baked goods, 22.6 % (SD = 29.0) drinking,
20.0 % (SD = 10.8) using a spray, and 13.5 % (SD = 13.4)
smoking a blunt.
Table 1 also shows sample characteristics stratified
among participants who reported current use of a vapouri-
zer and those who did not report current use of a vapouri-
zer. A logistic regression model (not shown) was fitted to
examine factors associated with Current modes of delivery.
Respondents with a high level of education had an
increased odds of currently using an alternative mode of
delivery compared to those with a low level of education
(AOR= 4.92, 95 % CI 1.44–16.84, p = 0.01) and those with
a moderate level of education (AOR = 5.00, 95 % CI 1.43–
16.67, p = 0.01). Respondents who used medical cannabis
mainly for “other” reasons had an increased odds of using
alternative modes of delivery compared to those who used
for pain relief, poor mental health, and central nervous
system illnesses (AOR= 3.41, 95 % CI 1.08–10.70, p = 0.04;
AOR = 9.09, 95 % CI 1.96–33.33, p = 0.01; and AOR=
16.67, 95 % CI 2.04–100.00, p = 0.01, respectively). Respon-
dents who used medical cannabis for relief of side effects
had increased odds of using alternative modes of delivery
compared to those using for poor mental health and central
nervous system illnesses (AOR= 8.91, 95 % CI 1.05–75.72,
p = 0.05 and AOR= 17.54, 95 % CI 1.33–231.28, p = 0.03,
respectively).
Respondents who perceived higher levels of harm from
smoking cannabis had an increased odds of currently
using alternative modes of delivery relative to those who
perceived the harm from smoking cannabis as “low”
(AOR = 16.90, 95 % CI 3.88–73.62, p < 0.01) or “moderate”
(AOR = 16.67, 95 % CI 2.13–100.00, p < 0.01). Those who
reported having a lower number of respiratory symptoms
had a higher odds of currently using alternative modes of
delivery (AOR = 1.61, 95 % CI 1.16–2.17, p < 0.01). In
terms of smoking cigarettes, non-smokers or “occasional”
smokers also had higher odds of using alternative modes
of delivery compared to daily smokers (AOR = 6.25, 95 %
CI 1.56–25.00, p = 0.01 and AOR = 6.23, 95 % CI 0.38–
23.83, p = 0.01, respectively). No other significant differ-
ences were observed by gender, age, ethnicity, income, or
region.
Vapourizer use
Overall, 77.2 % (n = 281) of respondents were aware of
vapourizing or vaping prior to the study, 11.5 % (n = 42)
of respondents were not aware of vapourizing or vaping
before the study, 3.3 % (n = 12) of respondents did not
know, and 8.0 % (n = 29) of respondents refused to
answer. A total of 71.6 % reported trying a vapourizer;
among those individuals, 28.3 % reported daily vapouri-
zer use over the past 30 days, 18.3 % used a vapourizer
almost every day over the past 30 days, 14.2 % used a
vapourizer at least once a week in the past 30 days, 19.2
% used a vapourizer at least once in the last 30 days, and
20.0 % had used a vapourizer, but not in the past month.
Respondents were asked to report the use of different
forms of cannabis in a vapourizer. Among those who Ever
used a vapourizer, virtually all had used dried herb in a
vapourizer (97.5 %), followed by cannabis resin (19.6 %),
butane extract (18.8 %), oil (14.6 %), and an alcohol or
carbon dioxide extract (1.7 %). Current users reported
similar proportions of using different forms (data not
shown). With respect to the type of vapourizer used, a ma-
jority of current users reported using a portable vapourizer
(67.2 %), followed by a stationary vapourizer 41.7 %, and
an e-cigarette or vape pen (19.3 %).
A logistic regression model (not shown) was fitted
to examine factors associated with the Current use
of vapourizers. Males (AOR = 2.46, 95 % CI 1.30–
4.76, p < 0.01), younger age (AOR = 1.03, 95 % CI
1.00–1.05, p = 0.05), “white” ethnicity (AOR = 2.52,
95 % CI 1.03–6.19, p = 0.04), and those with fewer
respiratory symptoms (AOR = 1.28, 95 % CI 1.05–
1.56, p = 0.01) reported a higher odds of Current use
of vapourizers. In addition, significant differences
were observed between regions (p = 0.02): respon-
dents from the Prairie Provinces (AOR = 5.69, 95 %
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Table 1 Sample characteristics
Characteristics Overall Current vapourizer use No current vapourizer use
(N = 364) (N = 192) (N = 102)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 40.8 (12.6) 41.2 (1.0) 44.3 (1.2)
% (n) % (n) % (n)
Gender
Male 57.7 (210) 67.2 (129) 52.9 (54)
Female 42.3 (154) 32.8 (63) 47.1 (48)
Ethnicity
White only 74.7 (272) 86.5 (166) 78.4 (80)
Mixed/other/missing 25.3 (92) 13.5 (26) 21.6 (22)
Education
Low 29.1 (106) 22.4 (43) 34.3 (35)
Moderate 46.7 (170) 49.5 (95) 49.0 (50)
High 22.0 (80) 27.1 (52) 16.7 (17)
Not reported 2.2 (8) – –
Income
Low 58.5 (213) 56.8 (109) 63.7 (65)
Middle 18.1 (66) 19.8 (38) 17.6 (18)
High 14.0 (51) 17.7 (34) 9.8 (10)
Not reported 9.4 (34) 5.7 (11) 8.8 (9)
Region
Ontario 50.3 (183) 64.1 (123) 46.1 (47)
British Columbia 15.1 (55) 15.1 (29) 18.6 (19)
Atlantic 13.2 (48) 13.0 (25) 8.8 (9)
Prairies 13.0 (47) 4.7 (9) 16.7 (17)
Quebec 4.1 (15) 2.6 (5) 5.9 (6)
Northern 3.8 (14) – 2.9 (3)
Missing 0.5 (2) 0.5 (1) 1.0 (1)
Cigarette smoking status
Not at all 58.5 (213) 76.7 (147) 59.8 (61)
Occasionally 16.2 (59) 6.3 (12) 8.8 (9)
Daily 19.2 (70) 17.2 (33) 30.4 (31)
Missing 6.1 (22) – 1.0 (1)
Main medical reason
Pain relief 44.8 (163) 57.8 (111) 51.0 (52)
Mental health 15.1 (55) 16.7 (32) 16.7 (17)
Central nervous system 9.9 (36) 8.9 (17) 8.8 (9)
Side effects 3.0 (11) 2.6 (5) 3.9 (4)
Other 12.4 (45) 13.0 (25) 14.7 (15)
Do not know 8.5 (31) 0.5 (1) 2.0 (2)
Refuse to answer 6.3 (23) 0.5 (1) 2.9 (3)
Amount (g/day) 1.8 (1.6) 1.8 (0.1) 1.6 (0.2)
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CI 1.50–21.50, p = 0.01) and from Ontario and
Northern regions (AOR = 5.29, 95 % CI 1.73–16.19,
p < 0.01) had a higher odds of currently using a
vapourizer than those from the Atlantic Canadian
Provinces. No significant differences were observed
for education, income, main medical reason for
using cannabis, and perceived harm of cannabis
smoking.
A regression model was conducted to examine the
association between vapourizer use and respiratory
symptoms in more detail. Using a vapourizer was sig-
nificantly associated with lower respiratory symptoms
(B = −0.40, p = 0.049) after adjusting for cigarette
smoking status, as well as age, gender, ethnicity,
education, income, and main medical reason for
cannabis use.
Perceptions of modes of delivery
Respondents were asked to rate three modes of delivery—
smoking, using a vapourizer, and eating in food—along 12
different dimensions using a scale range from 1 to 5 for
each dimension. Table 3 shows the mean rating by mode
of delivery for each of the 12 dimensions. ANOVA models
were run to test for differences in the mean rating be-
tween the three modes, for each of the 12 dimensions. As
indicated by the superscript letters in Table 3, time to on-
set of effect was rated as significantly faster for smoking,
followed by using a vapourizer, and then eating in food.
Smoking was rated as significantly lower cost and more
accessible than using a vapourizer or eating in food. How-
ever, using a vapourizer and eating in food was rated as
having a lower level of perceived harm than smoking.
Using a vapourizer was rated as easiest to use, and the
number of side effects was rated significantly lower for
Table 1 Sample characteristics (Continued)
Past 3-month frequency
Less than almost every day 20.0 (73) 4.7 (9) 19.6 (20)
Almost every day 21.2 (77) 24.0 (46) 26.5 (27)
Every day 55.8 (203) 71.4 (137) 53.9 (55)
Do not know/refuse to answer 3.0 (11) – –
Number of times per daya
Once 15.9 (58) 14.1 (27) 24.5 (25)
More than once 82.4 (300) 86.0 (165) 75.4 (77)
Do not know/refuse to answer 1.7 (6) – –
aNumber of times per day represents the average number of times that medical cannabis was used per day on the days that medical cannabis was used in the
past 30 days
Table 2 Prevalence of modes of delivery (N = 364)
Mode Ever use Current use Preferred
% (n) % (n) % (n)
Smoked modes
Smoking a joint 74.2 (270) 47.0 (171) 23.1 (84)
Smoking a pipe 61.3 (223) 25.8 (94) 4.9 (18)
Smoking a bong/waterpipe 53.6 (195) 21.4 (78) 8.5 (31)
Smoking a blunt 38.7 (141) 4.7 (17) 1.1 (4)
At least one smoked 77.2 (281) 58.8 (214) 37.6 (137)
Alternative modes
Using a vapourizer 65.9 (240) 52.7 (192) 28.3 (103)
Eating in foods 64.1 (234) 31.0 (113) 7.1 (26)
Drinking 29.9 (109) 5.5 (20) 1.6 (6)
Taking a pill 28.6 (104) 3.3 (12) 0.8 (3)
Using a spray 8.2 (30) 1.1 (4) 0.3 (1)
Other 10.4 (38) 8.0 (29) 4.7 (17)
At least one alternative 76.1 (277) 63.7 (232) 42.9 (156)
Do not know 9.6 (35) 9.6 (35) 10.4 (38)
Refuse to answer 9.6 (35) 9.9 (36) 9.9 (36)
Table 3 Perceptions of modes of delivery by dimension
(n = 342)




Mean (SD) Mean (SD) Mean (SD)
Time to onset of effect 4.1 (1.0)a 3.8 (1.1)a 2.1 (1.2)a
Symptom relief 4.0 (0.9)a 3.9 (1.0)b 3.9 (1.2)c
Accessibility 3.9 (1.2)a 3.6 (1.2)a 3.1 (1.4)a
Type of “high” 3.8 (1.0)a 3.8 (1.0)b 3.6 (1.1)ab
Ease of use 3.7 (1.2)a 3.8 (1.1)b 3.5 (1.4)b
Ability to find correct dose 3.7 (1.2)a 3.7 (1.2)b 2.6 (1.3)ab
Number of side effects 3.6 (1.2)a 4.0 (1.1)ab 3.7 (1.2)b
Duration of effect 3.4 (0.9)a 3.3 (1.0)b 4.2 (1.0)ab
Level of harm 3.3 (1.3)ab 4.2 (1.0)a 4.2 (1.1)b
Amount needed for effect 3.1 (1.0)a 3.2 (1.2)b 2.4 (1.2)ab
Cost 2.4 (1.2)ab 2.2 (1.2)a 2.2 (1.1)b
Stigma 2.4 (1.3)a 2.9 (1.3)a 3.3 (1.3)a
Rating was completed on a scale from 1 to 5, where 1 represented the least
desired effect and 5 represented the most desired effect. Values with the same
letter (a, b, c) are significantly different at a p < 0.05 tested using an ANOVA
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using a vapourizer compared to smoking or eating in food.
Eating in foods was rated as producing the worst high,
most stigma, was the hardest to find a correct dose, but
had the longest duration of effect. Lastly, perceptions of
symptom relief did not differ by mode.
Perceptions of vapourizer use
Among respondents who currently used a vapourizer
(n = 192), reported reasons for current vapourizer use
were they are less harmful to me than smoking canna-
bis (79.7 %, n = 153), it does not smell as much as
smoking cannabis (71.4 %, n = 137), easy to use (58.9 %,
n = 113), uses less cannabis (56.8 %, n = 109), less harm-
ful to people around me than smoking (51.0 %, n = 98),
less side effects (40.1 %, n = 77), easy to find the correct
dose (39.6 %, n = 76), provides the best symptom relief
(34.4 %, n = 66), effects occur faster (27.1 %, n = 52),
effects last longer (23.4 %, n = 45), provides the best
high (20.8 %, n = 40), more affordable (16.7 %, n = 32),
more accessible (15.6 %, n = 30), other people I know
use a vapourizer too (11.5 %, n = 22), it is fun to use
(11.5 %, n = 22), and other (9.4 %, n = 18).
Respondents who were aware of vapourizers, but had
never used them (n = 41), were asked to report their
main reason for not using a vapourizer. A total of 26.8 %
reported they were simply not interested in using a
vapourizer, followed by concerns about affordability
(19.5 %) and difficulty using a vapourizer (9.8 %). Over-
all, 73.2 % of never users indicated they would be willing
to try a vapourizer in the future.
Respondents who were aware of vapourization were
asked about their perceptions regarding the acceptability
and harm of vapourizing. As Table 4 shows, a majority
of respondents felt that vapourizers were more accept-
able to use compared to smoking, while a strong major-
ity reported that vapourizers were less harmful than
smoking. Almost half reported that vapourizing is “not
at all harmful”.
Personal importance of dimensions by mode of delivery
Respondents were asked to rate the importance of each
dimension in their choice of how to use cannabis. As
indicated in Table 5, symptom relief was rated as the
most important dimension when selecting the mode of
delivery, followed by cost, whereas the least important
dimension was stigma.
Discussion
The current study provides the most comprehensive
assessment of consumer perceptions and use of delivery
modes among medical cannabis users to date. The
findings suggest a possible shift in the popularity of
modes of delivery among approved medical users. Using
a vapourizer was the most common and the most
preferred mode of delivery. Overall, alternative modes
were slightly more popular than smoking, even though
the MMPR restricted the use and sale of medical canna-
bis to only dried herb, which is most easily smoked. Pre-
vious studies of medical users all found that smoking
was the most commonly used and most preferred mode,
in contrast to the current study’s findings [7–9, 27–30].
Among past studies that examined vapourizer use, the
Table 4 Perceptions of vapourization among those who are
aware of vapourization (n = 279)
Perceptions % (n)
Relative acceptability of vapourizers
Less acceptable than smoking 5.4 (15)
As acceptable as smoking 27.2 (76)
More acceptable than smoking 59.1 (165)
Do not know 0.4 (1)
Refuse to answer 7.9 (22)
Harm of vapourizing
Not at all harmful 48.0 (134)
A little or somewhat harmful 38.7 (108)
Very or extremely harmful 0.7 (2)
Do not know 12.2 (34)
Refuse 0.4 (1)
Relative harm of vapourizing
Less harmful than smoking 82.8 (231)
As harmful as smoking 6.5 (18)
More harmful than smoking 1.1 (3)
Do not know 8.9 (25)
Refuse to answer 0.7 (2)
Table 5 Important dimensions for selecting modes of delivery
(N = 364)
Dimensions Rating of importance
Mean (SD)
Symptom relief 4.5 (0.9)
Cost 4.2 (1.0)
Duration of effect 4.1 (1.0)
Accessibility 4.0 (1.1)
Amount needed for effect 4.0 (1.1)
Time to onset of effect 4.0 (1.1)
Ability to find correct dose 4.0 (1.1)
Ease of use 3.9 (1.1)
Type of “high” 3.8 (1.2)
Number of side effects 3.7 (1.3)
Level of harm 3.6 (1.4)
Stigma 2.6 (1.4)
Rating was completed on a scale from 1 to 5, where 1 represented not
important at all and 5 represented extremely important
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prevalence of using a vapourizer was generally low,
falling between 8 and 20 % [7, 28, 29]. However, one
Canadian study, conducted in 2007, found that 88 % of
approved medical users smoked, 72 % ate it, and 52 %
used a vapourizer, which offers similar estimates to the
current study [27]. Overall, the findings indicate a sub-
stantial shift towards the use of vapourizers and alterna-
tive modes of delivery among a sample of approved
Canadian medical cannabis users.
The popularity of vapourizers for using cannabis may
have been influenced by the recent increase in awareness
and use of e-cigarettes, which vapourize nicotine [23].
Most of the respondents who used a vapourizer reported
using a portable type of vapourizer, which is similar in
style to an e-cigarette. The findings suggest a shift away
from “stationary” vapourizers, such as the Volcano, which
was reported as the most commonly used vapourizer in
two previous studies among both medical and recreational
cannabis users [6, 22]. Unfortunately, “stationary” vapouri-
zers have better temperature control to ensure no com-
bustion is occurring whereas “portable” vapourizers or
vape pens are more likely to be heated quickly to a pre-set
temperature using a battery, which can increase the likeli-
hood for combustion possibly resulting in increased levels
of toxicants [20, 31].
Findings from the current study add to the previous
literature showing current use of alternative modes of
delivery and current use of a vapourizer are associated
with reporting fewer respiratory symptoms [13, 19, 32].
Using non-combustible modes could prevent some of
the negative respiratory health consequences associated
with smoking and may serve as an effective harm reduc-
tion method for the delivery of therapeutic relief through
medical cannabis. Respondents perceived smoking and
vapourizing as fairly similar on the 12 dimensions, with
the exception that smoking was perceived as signifi-
cantly more harmful, while vapourizing was associated
with the fewest side effects. These findings suggest that
most medical cannabis users who use a vapourizer do so
because they are aware and understand that using a
vapourizer reduces the negative health consequences
linked with smoking. General concerns about smoking-
related health consequences have also been noted by
respondents in previous research [6, 7]. The current rise
in health promotion, in terms of tobacco and smoking
prevention legislation at all levels of government, most
likely has also influenced the increase in vapourizer use
as opposed to smoking.
Respondents did identify several perceived advantages
to smoking; most notably, it provides the fastest time to
onset of effects. However, past scientific data reported
using a vapourizer and smoking produced similar blood
cannabinoid concentration levels over the same time
frame [2, 18]. Future research should examine the
delivery kinetics of vapourizing versus smoking given
the importance to users and, potentially, the therapeutic
benefits of medical cannabis. Indeed, symptom relief was
rated as the most important dimension when deciding
which mode of delivery to use, suggesting that approved
medical users prefer the mode that relieves their symp-
toms most effectively. However, respondents’ percep-
tions of the modes did not differ on symptom relief,
indicating that each mode of delivery—smoking, using a
vapourizer, and eating in foods—provided similar symp-
tom relief. Given the range of medical reasons by which
approved users have obtained approval, future research
should explore whether particular modes of delivery are
better suited for specific types of symptom relief. For
example, acute pain relief may benefit from modes with
faster onset, whereas chronic conditions may benefit
from modes with longer duration of effect. These princi-
ples are well established with respect to modes of deliv-
ery for pharmaceutical drugs but have yet to be explored
for medical cannabis use.
Finally, cost was cited as the second most important
dimension when selecting delivery modes. Eating in
foods and using a vapourizer were both perceived as the
most expensive, and smoking the least expensive mode.
Previous studies have also cited cost as a main reason
for not using a vapourizer [22, 33]. For example, one
study reported a mean cost of approximately $250 to
purchase a vapourizer [22]. Cost may be important to
medical cannabis users as cost coverage for medical
cannabis use in general is low in Canada [34]. However,
given the rise in popularity of the use of e-cigarette
devices, the cost associated with vapourizing technology
is dropping and portable devices for vapourizing similar
to e-cigarettes are much less expensive compared to
stationary vapourizers.
Strengths and limitations
The current study has a number of strengths and limi-
tations. A convenience sample was recruited through
licensed producers as probability sampling was not
feasible. Only approved medical cannabis users were
eligible to take part in the survey, thus excluding med-
ical users who were not approved. There is no way to
determine whether the current sample is the represen-
tative of the population of approved medical cannabis
users in Canada due to a lack of publicly accessible
information on this population. However, in 2013,
Health Canada released information showing that the
majority of Canadians with medical cannabis approval
resided in British Columbia, accounting for nearly half
of all licensed medical users in Canada, followed by
Ontario at approximately 30 % [5]. Therefore, the current
sample may have potentially under represented British
Columbia residents and over represented Ontario residents.
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Additional research on the profile of medical cannabis users
in Canada would be an asset, particularly with respect to
comparisons between approved and non-approved users.
Finally, the survey relied on self-report, which may contrib-
ute to a number of biases, including recall bias and social
desirability bias. For example, about a quarter of partici-
pants responded “I don't know”, “Other”, or “Refuse to
answer” when asked what their main reason for medical
cannabis use was. In addition, the survey was cross-
sectional; thus, a temporal order could not be established.
Strengths of the study include a systematic recruit-
ment of a large sample of approved medical cannabis
users from across Canada. This is one of the first studies
to only include approved Canadian medical cannabis
users, which is the population directly impacted by
medical cannabis regulations. The timeliness of the data
was also a major strength as it was important to assess
the possible implications of the MMPR, which to our
knowledge had not been examined until the current
study.
Conclusions
This study presents a general picture of the current state of
medical cannabis use among a sample of approved users in
Canada. The findings indicate that approved users have
tried multiple modes of delivery, but using a vapourizer was
the most commonly used and most preferred mode. The
findings suggest that increasing availability and lowering
the cost of vapourizers is likely to reduce the prevalence of
smoking medical cannabis even further, with the added
benefits of reducing harm linked to smoking. Currently, it
is unclear what, if any, guidance is being provided to
medical cannabis users from physicians, health authorities,
or licensed producers with respect to modes of delivery.
More generally, the findings highlight the importance of
monitoring patterns of medical cannabis use to a greater
extent. For example, a Quebec Cannabis registry has been
created in order to track patient use information, as well as
monitor patient safety; national registries based on this
model have the potential to inform medical cannabis policy,
particularly given recent changes in federal regulation.
Acknowledgements
Thank you to Alana Watson for her assistance in this project.
Funding
Support was provided by a Canadian Institute of Health Research (CIHR) Training
Grant Program in Population Intervention for Chronic Disease Prevention (Grant
No. 53893; SS), a Social Science Graduate Student Research Award from
the Canadian Consortium for the Investigation of Cannabinoids (SS), a
CIHR New Investigator Award (DH), and a CIHR Public Health Agency of
Canada Chair in Applied Public Health (DH).
Availability of data and materials
The datasets generated during and/or analysed during the current study are
not publicly available due to confidentiality reasons but are available from
the corresponding author on reasonable request.
Authors’ contributions
SS programmed the survey and recruited the participants, analysed and
interpreted the data, and drafted the manuscript. DH conceptualized and
designed the project, revised the manuscript, and has agreed to be
accountable for all aspects of the work. All authors read and approved the
final manuscript.
Competing interests
The authors’ declare that they have no competing interests.
Consent for publication
Consent was provided by each participant via a consent form completed
before the survey began.
Ethics approval and consent to participate
This study received ethics clearance through the University of Waterloo
Research Ethics Committee.
Author details
1School of Public Health & Health Systems, University of Waterloo, 200
University Ave W, Waterloo, ON N2L 3G1, Canada. 2Centre for Clinical
Research, Dalhousie University, Halifax, Canada.
Received: 17 August 2016 Accepted: 21 October 2016
References
1. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of
marijuana use. N Engl J Med. 2014;370(23):2219–27.
2. Canada H. Information for health care professionals cannabis (marihuana,
marijuana) and the cannabinoids. 2013. Retrieved from: http://www.hc-sc.
gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf .
Accessed 5 Sept 2014.
3. Canada H. Canadian alcohol and drug use monitoring survey. 2012. http://
www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.
php . Accessed 23 Nov 2014.
4. Canada H. Canadian alcohol and drug use monitoring survey. 2014. http://
www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.
php . Accessed 23 Nov 2014.
5. Canada H. Marihuana medical access program (MMAR) statistics 2013. 2014.
http://www.hc-sc.gc.ca/dhp-mps/marihuana/stat/index-eng.php . Accessed
2 Feb 2015.
6. Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F.
The medicinal use of cannabis and cannabinoids—an international
cross-sectional survey on administration forms. J Psychoactive Drugs.
2013;45(3):199–210.
7. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical
purposes. Harm Reduction J. 2005;2:18.
8. Ware MA, Tawfik VL. Safety issues concerning the medical use of cannabis
and cannabinoids. Pain Res Manag. 2005;10(Supplement A):31A–7A.
9. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic
non-cancer pain: results of a prospective survey. Pain. 2003;102(1–2):211–6.
10. Hathaway AD. Cannabis users’ informal rules for managing stigma and risk.
Deviant Behav. 2004;25(6):559–77.
11. Ogborne AC, Smart RG, Adlaf EM. Self-reported medical use of marijuana: a
survey of the general population. Can Med Assoc J. 2000;162(12):1685–6.
12. Bottorff JL, Bissell LJ, Balneaves LG, Oliffe JL, Capler NR, Buxton J.
Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive
study. Harm Reduct J. 2013;10 (2). DOI: 10.1186/1477-7517-10-2.
13. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis
users who vaporize. Harm Reduction J. 2007;4:11.
14. Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health:
consideration of the literature. Respirology. 2014;19(5):655–62.
15. Fischer B, Imtiaz S, Rudzinski K & Rehm J. Crude estimates of cannabis-
attributable mortality and morbidity in Canada—implications for public
health focused intervention priorities. Journal of Public Health (Oxford,
England). 2015; Advanced online publication.
16. Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang Z, Cozen W, Mack TM,
Greenland S. Marijuana use and the risk of lung and upper aerodigestive
tract cancers: results of a population-based case–control study. Cancer
Epidemiol Biomarkers Prev. 2006;15(10):1829–34.
Shiplo et al. Harm Reduction Journal  (2016) 13:30 Page 9 of 10
17. O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical
cannabis in California (2001–2007): demographics, social characteristics,
patterns of cannabis and other drug use of 4117 applicants. Harm
Reduction J. 2007;4:16.
18. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization
as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther.
2007;82(5):572–8.
19. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support
for a clinical trial of the vaporizer. Int J Drug Policy. 2010;21(6):511–3.
20. Pomahacova B, Van Der Kooy F, Verpoorte R. Cannabis smoke condensate
III: the cannabinoid content of vaporised cannabis sativa cannabinoid
content of vaporised cannabis sativa. Inhal Toxicol. 2009;21(13):1108–12.
21. Gieringer D, St Laurent J, Goodrich S. Cannabis vaporizer combines
efficient delivery of THC with effective suppression of pyrolytic
compounds. J Cannabis Ther. 2004;4(1):7–27.
22. Malouff JM, Rooke SE, Copeland J. Experiences of marijuana-vaporizer users.
Subst Abus. 2014;35(2):127–8.
23. Czoli C, Reid J, Rynard V, Hammond D. E-cigarettes in Canada—tobacco use
in Canada: patterns and trends, 2015 edition, special supplement. 2015.
http://www.tobaccoreport.ca/2015/TobaccoUseinCanada_2015_
EcigaretteSupplement.pdf . Accessed 8 July 2015.
24. Czoli CD, Hammond D, White CM. Electronic cigarettes in Canada:
prevalence of use and perceptions among youth and young adults.
Can J Public Health. 2014;105(2):e97–e102.
25. Thrasher JF, Quah AC, Dominick G, Borland R, Driezen P, Awang R, Omar M,
Hosking W, Sirirassamee B, Boado M. Using cognitive interviewing and
behavioral coding to determine measurement equivalence across linguistic
and cultural groups: an example from the International Tobacco Control
Policy Evaluation Project. Field Methods. 2011;23(4):439–460.
26. The American Association for Public Opinion Research (AAPOR). Standard
definitions: final dispositions of case codes and outcome rates for surveys
8th edition. 2015. https://www.aapor.org/AAPOR_Main/media/publications/
Standard-Definitions2015_8theditionwithchanges_April2015_logo.pdf.
Accessed 8 July 2015.
27. Lucas P. It can’t hurt to ask; a patient-centered quality of service
assessment of health Canada’s medical cannabis policy and program.
Harm Reduction J. 2012;9(2):b23.
28. Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical
marijuana patients? Population characteristics from nine California
assessment clinics. J Psychoactive Drugs. 2011;43(2):128–35.
29. Belle-Isle L, Hathaway A. Barriers to access to medical cannabis for
Canadians living with HIV/AIDS. AIDS Care. 2007;19(4):500–6.
30. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as
described by people with multiple sclerosis. Can J Neurol Sci. 2003;30(3):201–5.
31. Hazekamp A, Ruhaak R, Zuurman L, Van Gerven J, Verpoorte R. Evaluation of
a vaporizing device (volcano®) for the pulmonary administration of
tetrahydrocannabinol. J Pharm Sci. 2006;95(6):1308–17.
32. Earleywine M, Van Dam NT. Case studies in cannabis vaporization. Addict
Res Theory. 2010;18(3):243–9.
33. Mitchell IV. Vaporizer legalization. Can Med Assoc J. 2014;186(12):937–0062.
34. The Huffington Post. Medical marijuana insurance coverage awarded to
Jonathan Zaid, Waterloo student. 2015. http://www.huffingtonpost.ca/2015/
03/16/medical-marijuana-insurance-sun-life-jonathan-zaid_n_6881578.html .
Accessed 3 July 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shiplo et al. Harm Reduction Journal  (2016) 13:30 Page 10 of 10
